Spots Global Cancer Trial Database for Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Official Title: Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Study ID: NCT03739775

Conditions

HPV Positive Pelvic Cancer

Interventions

Blood sampling

Study Description

Brief Summary: ctDNA detection in patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up.

Detailed Description: Patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up will be included. These patients will be followed up during 30 months (2.5 years) (if no relapse occurred before) with ctDNA detection performed at each hospital visit. At each visit, clinical, biological (squamous cell carcinoma (SCC) serum marker will be done systematically) and radiological/pathology (if any) results will be prospectively collected in the study. For the patients who have a relapse or new HPV-induced invasive cancer before 30 months, the follow-up will be discontinued at the date of the relapse. For the patients who will have completed their follow-up for the study (2.5 years) with no relapse or new HPV-induced invasive cancer, they will be followed up for 6 months (+ 14 days), to collect any late relapse (if any). None specific study procedure will be performed during this period.